Psst...use this combination if you want to make it through clinical trials to market
Effective action of drugs at their targets and reliably correct diagnoses of diseases and conditions have one very important thing in common, the correct selection of and interaction with the biomarkers used for targeting the drug or 'tagging' the disease from the start. Most failures of drugs in the clinical stage are related to the initial failure to correctly identify these interactions. To address this time-consuming and costly problem, the German SME Surflay Nanotec has developed WhisperSense, the first commercial label-free bioanalysis platform exploiting individual microparticles as label-free biosensors. The tiny spherical microparticles can be functionalised to recognise specific biological entities. The highly sensitive and specific platform also supports high-throughput screening. EU funding of the WhisperSense project helped the team improve technical performance, evaluate feasibility and develop a credible business plan.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesbiological sciencesbiological behavioural sciencesethologybiological interactions
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
Call for proposalSee other projects for this call